Compounded vs. brand-name semaglutide: what you are choosing

Novo Nordisk sells semaglutide under three names in 2026: Ozempic (weekly injection and, since May 2026, a daily tablet, both for type 2 diabetes), Rybelsus (the original tablet, sharing one label with the Ozempic pill) and Wegovy (weekly injection, the 7.2 mg Wegovy HD dose, and a daily tablet for weight management). Each is made to an approved specification in inspected facilities.

Compounded semaglutide reaches you through one of two federal routes. A 503A pharmacy compounds against individual prescriptions, is overseen mainly by its state board of pharmacy, and is not required to follow current good manufacturing practice (CGMP). A 503B outsourcing facility registers with FDA, must meet CGMP and is inspected on a risk-based schedule. Neither route amounts to approval, and FDA says plainly that it does not review compounded drugs for safety, effectiveness or quality before they are sold.

No trial has put a compounded semaglutide against any brand product, so there is no head-to-head result to report. The efficacy evidence is all brand evidence: in STEP 1, semaglutide 2.4 mg weekly (Wegovy's dose) produced a mean weight change of −14.9% against −2.4% on placebo over 68 weeks, and SELECT reported a 20% lower risk of major cardiovascular events in people with established heart disease and overweight or obesity.

For a compounded product, the evidence that actually applies is quality evidence, and FDA reports three problems. First, adverse events: as of 31 May 2026 it had received 990 reports linked to compounded semaglutide, some tied to dosing errors and some needing hospital care. Second, salt forms: FDA says some compounders may use semaglutide sodium or semaglutide acetate, which it calls different active ingredients from the one in the approved drugs, with no information on whether they behave the same. Third, marketing: in February 2026 FDA said sellers may not describe compounded products as generics or as clinically proven. A report is not proof of cause, but it is the only safety signal that exists for these products.

The label effects are the same list whichever box the product comes in. Ozempic's prescribing information names nausea, vomiting, diarrhoea, abdominal pain and constipation as the reactions seen in at least 5% of patients. The warnings cover pancreatitis, gallbladder disease, kidney injury from dehydration, diabetic retinopathy complications and aspiration under anaesthesia, and every semaglutide label carries the boxed warning on thyroid C-cell tumours in rodents, ruling out anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

The compounded route adds handling risks rather than new pharmacology. FDA advises using a multi-dose sterile vial within 28 days of first puncture because contamination risk rises after that, and it has logged hospitalisations linked to dosing mistakes. Some compounded vials also carry an added ingredient, such as glycine or vitamin B12, that no brand product contains.

If your plan covers Ozempic or Wegovy, or the self-pay price works, the brand removes the quality questions entirely. That price has moved: NovoCare Pharmacy lists Wegovy pens at $199 a month for the first two fills, then $349 (NovoCare Pharmacy, checked 28 Sep 2026).

Compounded semaglutide suits people for whom that number, or a coverage denial, still rules the brand out, and who will do the checking the label would otherwise do for them. Before the first fill, ask four questions:

• Is the pharmacy a 503A pharmacy or a 503B outsourcing facility, and is it licensed in your state?
• Is the active ingredient semaglutide base, or a salt form?
• Is each batch tested for potency and sterility, and will they share the certificate of analysis?
• What is the concentration, and what is the beyond-use date?

If a pharmacy will not answer those, choose another. Neither route suits anyone with a history of medullary thyroid carcinoma or MEN 2, and pancreatitis or pregnancy plans need a prescriber's input first.